The link between hyperglycaemia and diabetic nephropathy - PubMed (original) (raw)

Review

. 1992 Jun;35(6):499-504.

doi: 10.1007/BF00400475.

Affiliations

• PMID: 1612221
• DOI: 10.1007/BF00400475

Review

The link between hyperglycaemia and diabetic nephropathy

R G Larkins et al. Diabetologia. 1992 Jun.

Erratum in

• Diabetologia 1992 Nov;35(11):1100

Abstract

A large number of experimental studies in animals and retrospective or non-randomised prospective studies in humans provide support for the concept that the microvascular complications of diabetes mellitus are dependent on hyperglycaemia. This review focuses on four potential biochemical pathways linking hyperglycaemia to changes within the kidney which can plausibly be linked to the functional and structural changes characterising diabetic nephropathy. These four pathways are the polyol pathway, non-enzymatic glycation, glucose autoxidation and de novo synthesis of diacylglycerol leading to protein kinase C and phospholipase A2 activation. Rather than being independent, there are several potential interactions between these four pathways which may explain confusing and overlapping effects observed in studies examining inhibitors of individual pathways. As many of the steps which follow on glucose metabolism are subject to modification by dietary and pharmacological means, the further delineation of the pathogenetic sequence leading to tissue damage in diabetes should allow a logical and effective approach to the prevention or treatment of the complications of diabetes.

PubMed Disclaimer

Similar articles

• Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
  Stribling D, Armstrong FM, Harrison HE. Stribling D, et al. J Diabet Complications. 1989 Apr-Jun;3(2):70-6. doi: 10.1016/0891-6632(89)90015-9. J Diabet Complications. 1989. PMID: 2526143 Review.
• Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
  ElGamal H, Munusamy S. ElGamal H, et al. Protein Pept Lett. 2017;24(1):71-77. doi: 10.2174/0929866523666161128153548. Protein Pept Lett. 2017. PMID: 27894247 Review.
• Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation.
  Keogh RJ, Dunlop ME, Larkins RG. Keogh RJ, et al. Metabolism. 1997 Jan;46(1):41-7. doi: 10.1016/s0026-0495(97)90165-7. Metabolism. 1997. PMID: 9005967
• Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
  Sheetz MJ, King GL. Sheetz MJ, et al. JAMA. 2002 Nov 27;288(20):2579-88. doi: 10.1001/jama.288.20.2579. JAMA. 2002. PMID: 12444865 Review.
• The pathogenesis and prevention of diabetic neuropathy and nephropathy.
  Greene D. Greene D. Metabolism. 1988 Feb;37(2 Suppl 1):25-9. doi: 10.1016/0026-0495(88)90184-9. Metabolism. 1988. PMID: 2828823

Cited by

• Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function.
  Hinden L, Ahmad M, Hamad S, Nemirovski A, Szanda G, Glasmacher S, Kogot-Levin A, Abramovitch R, Thorens B, Gertsch J, Leibowitz G, Tam J. Hinden L, et al. Nat Commun. 2022 Apr 4;13(1):1783. doi: 10.1038/s41467-022-29124-8. Nat Commun. 2022. PMID: 35379807 Free PMC article.
• Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy.
  Chang YT, Chung MC, Hsieh CC, Shieh JJ, Wu MJ. Chang YT, et al. Toxins (Basel). 2021 Aug 10;13(8):560. doi: 10.3390/toxins13080560. Toxins (Basel). 2021. PMID: 34437430 Free PMC article.
• Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.
  Quarta C, Cota D. Quarta C, et al. Int J Obes (Lond). 2020 Nov;44(11):2179-2193. doi: 10.1038/s41366-020-0577-8. Epub 2020 Apr 21. Int J Obes (Lond). 2020. PMID: 32317751 Review.
• Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy.
  Ghavidel Darestani S, Kurano M, Shinnakasu A, Yamamoto K, Dochi Y, Uemura K, Ikeda Y, Arimura A, Arimura H, Kikuchi A, Hashiguchi H, Deguchi T, Nishio Y. Ghavidel Darestani S, et al. Diabetol Int. 2019 Apr 11;11(1):11-18. doi: 10.1007/s13340-019-00394-w. eCollection 2020 Jan. Diabetol Int. 2019. PMID: 31949999 Free PMC article.
• Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues.
  Ruiz de Azua I, Lutz B. Ruiz de Azua I, et al. Cell Mol Life Sci. 2019 Apr;76(7):1341-1363. doi: 10.1007/s00018-018-2994-6. Epub 2019 Jan 1. Cell Mol Life Sci. 2019. PMID: 30599065 Free PMC article. Review.

References

1. 1. N Engl J Med. 1989 Apr 6;320(14):915-24 - PubMed
2. 1. Invest Ophthalmol Vis Sci. 1983 Nov;24(11):1519-24 - PubMed
3. 1. Kidney Int Suppl. 1991 Apr;31:S29-34 - PubMed
4. 1. J Clin Endocrinol Metab. 1985 Jun;60(6):1231-6 - PubMed
5. 1. Diabetes. 1985 Apr;34(4):360-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program